Oncogene expression in autoimmune and normal peripheral blood mononuclear cells

doi:10.1084/jem.163.5.1292

This Article

	Full Text (PDF, 1682K)
	Alert me when this article is cited
	Citation Map

Services

	Email this article
	Similar articles in this journal
	Similar articles in PubMed
	Alert me to new content in the JEM
	Download to citation manager

Citing Articles

	Citing Articles via HighWire
	Citing Articles via CrossRef
	Citing Articles via Google Scholar

Google Scholar

	Articles by Klinman, D. M.
	Articles by Steinberg, A. D.
	Search for Related Content

PubMed

	PubMed Citation
	Articles by Klinman, D. M.
	Articles by Steinberg, A. D.


Social Bookmarking

	What's this?

ARTICLES

Oncogene expression in autoimmune and normal peripheral blood mononuclear cells

DM Klinman, JF Mushinski, M Honda, Y Ishigatsubo, JD Mountz, ES Raveche and AD Steinberg

PBMC from patients with autoimmune diseases and from normal controls were studied for the expression of several cellular oncogenes. Gene expression was assessed by Northern blot analysis of poly(A)+ RNA obtained from leukapheresis samples. Patients with SLE expressed significantly more c-myc protooncogene RNA than did normal controls. Increased expression of the N-ras protooncogene was found in that subset of patients whose autoimmune disease was very active. Cells from individuals with SLE, but not from those with other autoimmune illnesses, showed significantly decreased levels of the c-myb and c-fos protooncogenes. To examine the implications of these findings, B and T cells were purified from apheresis samples donated by normal volunteers. When mitogen was used to activate the B cells in vitro, their pattern of protooncogene expression changed to resemble that found in freshly isolated cells from lupus patients. These results suggest that the differences detected in the expression of protooncogenes by patients with SLE may be due to the abnormal activation of their B cells in vivo. The pattern of protooncogene expression found in patients with other autoimmune illnesses is consistent with the activation of additional cell types in those diseases.
Add to CiteULike CiteULike Add to Complore Complore Add to Connotea Connotea Add to Del.icio.us Del.icio.us Add to Digg Digg Facebook Add to Reddit Reddit Add to Technorati Technorati Twitter What's this?

This article has been cited by other articles:

Balada, E., Ordi-Ros, J., Serrano-Acedo, S., Martinez-Lostao, L., Vilardell-Tarres, M. (2007). Transcript overexpression of the MBD2 and MBD4 genes in CD4+ T cells from systemic lupus erythematosus patients. J. Leukoc. Biol. 81: 1609-1616 [Abstract] [Full Text]
Kyttaris, V. C., Juang, Y.-T., Tenbrock, K., Weinstein, A., Tsokos, G. C. (2004). Cyclic Adenosine 5'-Monophosphate Response Element Modulator Is Responsible for the Decreased Expression of c-fos and Activator Protein-1 Binding in T Cells from Patients with Systemic Lupus Erythematosus. J. Immunol. 173: 3557-3563 [Abstract] [Full Text]
Crispin, J C, Alcocer-Varela, J (1998). Interleukin-2 and systemic lupus erythematosus--fifteen years later. Lupus 7: 214-222 [Abstract]
Cheng, J, Zhou, T, Liu, C, Shapiro, J., Brauer, M., Kiefer, M., Barr, P., Mountz, J. (1994). Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science 263: 1759-1762 [Abstract]
STEINBERG, A. D., SELDIN, M. F., JAFFE, E. S., SMITH, H. R., KLINMAN, D. M., KRIEG, A. M., COSSMAN, J. (1988). Angioimmunoblastic Lymphadenopathy with Dysproteinemia. ANN INTERN MED 108: 575-584 [Abstract]